Drug Trial Radar · NCT03493282
Effect of CT1812 Treatment on Brain Synaptic Density
Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Mar 28, 2018
Primary completion
Oct 16, 2020
Study completion Oct 16, 2020
Sponsor
- Lead sponsor
- Cognition TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Apr 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
Conditions
- Alzheimer Disease
Interventions
Active Treatment- CT1812 100 mgDrug
CT1812
Active Treatment- CT1812 300 mgDrug
CT1812
PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of TEAEs, Related TEAEs, SAEs, and Related SAEsTime frame: Up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yale University School of Medicine
New Haven, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.